What Insurance Covers Mounjaro in 2026: Every Major Plan's Coverage Rules

Reviewed by FormBlends Medical Team · Last updated September 5, 2026 · 22 sources cited

Key Takeaways

• In a 2026 survey of 307 U.S. employers (IFEBP pulse survey, summarized by healthinsurance.org on August 20, 2026), 60% cover GLP-1 drugs for diabetes and 36% cover them for both diabetes and weight loss. Mounjaro's own label is diabetes-only, so weight-loss coverage, where it exists, routes to Zepbound
• Medicare Part D does not cover Mounjaro for weight loss under any circumstances due to statutory exclusions, though diabetes coverage varies by plan
• The three factors that determine coverage are diagnosis code (diabetes vs obesity), formulary tier placement (typically Tier 3 or specialty), and whether your plan categorizes GLP-1s as medical or pharmacy benefit
• An earlier version of this page cited Lilly approval-rate data that we could not find anywhere, so it has been removed. What we can verify is the criteria: UnitedHealthcare's commercial policy effective July 1, 2026 approves Mounjaro for 12 months on chart notes showing type 2 diabetes by lab value (A1C 6.5% or higher, fasting glucose 126 mg/dL or higher, or equivalent) and states that weight-loss use is typically excluded

The short answer

Most commercial insurance plans cover Mounjaro for type 2 diabetes with prior authorization, placing it on Tier 3 or specialty tiers with typical copays of $50 to $600 monthly. Weight-loss coverage is a Zepbound question, not a Mounjaro one, and 36% of surveyed employers offered it in 2026. Medicare excludes weight-loss coverage by law, although a $50 GLP-1 Bridge for Wegovy, Zepbound KwikPen and Foundayo began July 1, 2026 (Mounjaro is not included). Medicaid covers Mounjaro for diabetes with prior authorization; 13 states covered GLP-1s for obesity in January 2026 per KFF, and Massachusetts ended that coverage on July 1, 2026.

Table of contents

1. The coverage landscape: who pays, who doesn't
2. Commercial insurance coverage by plan type
3. The prior authorization gauntlet (and real approval rates)
4. Medicare Part D: why Mounjaro for weight loss is categorically excluded
5. Medicaid coverage by state (the 2026 map)
6. What most articles get wrong about "covered" vs "accessible"
7. The three-tier coverage decision tree
8. Employer self-funded plans: the wild card
9. The Lilly savings card and who it actually helps
10. When compounded tirzepatide costs less than insured Mounjaro
11. How to verify your specific coverage in under 10 minutes
12. UHC's 2026 PA criteria, quoted
13. Medicaid obesity coverage tracker, 2026
14. Medicare 2026 and the $50 Bridge
15. Employer and Marketplace coverage rates
16. Sleep apnea, prediabetes, no diabetes
17. Denied: the $499 fill and 2026 card caps
18. FAQ

The coverage landscape: who pays, who doesn't

Insurance coverage for Mounjaro exists in three distinct worlds with different rules:

World 1: Type 2 diabetes treatment. Mounjaro received FDA approval for type 2 diabetes in May 2022. Most commercial plans added it to formularies within 6 to 12 months. The best published number is from a 2026 survey of 307 employers: 60% cover GLP-1 drugs for diabetes (healthinsurance.org, August 20, 2026), nearly always with prior authorization. The medication sits on Tier 3 (non-preferred brand) or Tier 4 (specialty) in most formularies.

World 2: Weight loss (chronic weight management). This is where coverage collapses. Despite Zepbound (the same molecule, tirzepatide, branded for weight loss) receiving FDA approval in November 2023, most insurance plans explicitly exclude weight-loss medications from coverage. In the same 2026 survey of 307 employers, 36% said they cover GLP-1 drugs for both diabetes and weight loss, unchanged from 2025, and additional 2026 surveys found 5% to 10% of employers that cover weight-loss use plan to drop it in 2027 (healthinsurance.org, August 20, 2026). On the individual market, KFF's 2024 analysis found 1% of Marketplace plans covered Wegovy or Saxenda for weight loss and none covered Zepbound.

World 3: Off-label use. When a provider prescribes Mounjaro (the diabetes-branded version) off-label for weight loss, plans almost universally deny coverage. The diagnosis code on the prescription determines everything. ICD-10 code E11.9 (type 2 diabetes) gets processed through diabetes pathways. E66.01 (morbid obesity with BMI over 40) triggers automatic denials on most plans.

The question "Does my insurance cover Mounjaro?" has no single answer. The correct question is: "Does my insurance cover Mounjaro for my specific diagnosis, and what will I pay after prior authorization?"

Commercial insurance coverage by plan type

Plan category	Mounjaro coverage for diabetes	Mounjaro coverage for weight loss	Typical tier	PA required	Average copay (post-deductible)
Large employer PPO (500+ employees)	75-80% of plans	20-25% of plans	Tier 3	Yes	$75-$200
Large employer HDHP	60-70% of plans	10-15% of plans	Tier 3 or specialty	Yes	20-30% coinsurance ($200-$350)
Small employer plans (under 50 employees)	50-60% of plans	5-10% of plans	Tier 3	Yes	$100-$300
Marketplace (ACA) silver plans	55-65% of plans	Under 5% of plans	Tier 3 or 4	Yes	30-40% coinsurance ($250-$450)
Marketplace bronze plans	30-40% of plans	Rare	Specialty	Yes	Full cost until deductible met
Medicare Part D	40-50% of plans	0% (statutory exclusion)	Specialty	Yes	$200-$600
Medicaid (state-dependent)	Covered for diabetes with PA in state programs	13 states in January 2026 (KFF); several ended it during 2026, including Massachusetts on July 1	Varies	Yes	$0-$8 copay if covered

A note on the percentages in the commercial rows above: they are our editorial estimates from April 2026, not survey results, and we have not found a published source that breaks coverage out by plan size. The verifiable figures are the 2026 employer survey (60% cover GLP-1s for diabetes, 36% for weight loss too) and KFF's 2024 Marketplace analysis (1% covered Wegovy or Saxenda for weight loss, none Zepbound). The direction of the pattern, larger employers negotiating better placement, is consistent with those sources.

The prior authorization gauntlet (and real approval rates)

Prior authorization (PA) is the insurance industry's way of saying "we need proof this is medically necessary before we pay."

For Mounjaro, PA requirements typically include:

• Documented type 2 diabetes confirmed by a lab value. UnitedHealthcare's 2026 commercial policy, for example, accepts an A1C of 6.5% or higher, a fasting plasma glucose of 126 mg/dL or higher, a 2-hour glucose of 200 mg/dL or higher on a tolerance test, or a random glucose of 200 or higher with symptoms, or chart notes for a diagnosis more than two years old
• BMI over 27 with comorbidity or over 30 without (for weight-loss indication, if covered at all)
• Trial and failure of at least one other diabetes medication (metformin is the most common requirement)
• Documentation that the patient doesn't have contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2)

An earlier version of this page reported Lilly internal approval rates across 847,000 claims. We could not locate that publication or any equivalent, so those figures have been removed. Insurers publish criteria, not approval rates, and the UnitedHealthcare policy quoted in the new section below is the most specific public document we have found.

The approval gap between diabetes and weight loss is not clinical. It's contractual. Most plans exclude weight-loss drugs in their benefits design, regardless of FDA approval or medical necessity.

PA processing time averages 5 to 10 business days for standard review, 72 hours for expedited review (which requires provider documentation of urgent medical need). In our provider network's experience, the most common reason a first submission fails is missing documentation, usually the lab value or the chart note that confirms the diagnosis; we do not have a published denial rate to cite.

Medicare Part D: why Mounjaro for weight loss is categorically excluded

Medicare Part D plans can cover Mounjaro for type 2 diabetes. They cannot cover it for weight loss, even if a provider writes "medically necessary" on the prescription.

The reason is statutory, not clinical. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Part D plans from covering drugs used for weight loss or weight gain. The law lists this as a categorical exclusion alongside cosmetic treatments and over-the-counter medications.

This means:

• If your prescription says type 2 diabetes (ICD-10 E11.x), your Part D plan may cover Mounjaro (subject to formulary placement and PA)
• If your prescription says obesity (ICD-10 E66.x), your Part D plan will deny the claim, and no appeal will overturn it

The prohibition applies even when obesity is causing or worsening diabetes. A 68-year-old patient with type 2 diabetes and BMI of 38 can get Mounjaro covered for diabetes management, but the same patient cannot get it covered if the provider writes the prescription for weight reduction.

As of 2026, about 40-50% of Medicare Part D plans include Mounjaro on their formularies for diabetes. Those that do place it on specialty tier (Tier 5), with copays typically ranging from $200 to $600 per month during the initial coverage phase. Once a patient enters the coverage gap (the "donut hole"), cost-sharing increases until catastrophic coverage begins.

The Lilly savings card does not apply to Medicare patients. Federal anti-kickback statutes prohibit manufacturer copay cards for government-funded insurance.

The statutory exclusion still stands as of September 4, 2026, but CMS built a workaround around it: the Medicare GLP-1 Bridge, $50 a month from July 1, 2026 through December 31, 2027 for Wegovy, Zepbound KwikPen and Foundayo, with prior authorization, and outside the $2,100 Part D out-of-pocket cap. Mounjaro and Ozempic are not on the list (KFF, May 11, 2026).

Medicaid coverage by state (the 2026 map)

Medicaid is state-administered, so coverage varies dramatically by geography.

Every state Medicaid program covers Mounjaro for type 2 diabetes because it is a covered outpatient drug under the federal rebate program; the variable is the prior authorization criteria, not whether it is on the list. Obesity coverage is the real map. KFF counted 13 states covering GLP-1s for obesity under fee-for-service Medicaid as of January 2026, after California, New Hampshire, Pennsylvania and South Carolina ended it following October 2025 and North Carolina reinstated it in December 2025. Massachusetts then ended obesity coverage on July 1, 2026 (WBUR, June 23, 2026). Medicaid gross spending on GLP-1s grew from about $1 billion in 2019 to about $9 billion in 2024 (KFF, January 16, 2026), which is why states keep trimming.

State coverage tier	States	Diabetes coverage	Weight-loss coverage	Typical PA requirements
Obesity use covered (GLP-1s for weight management)	13 states as of January 2026 per KFF; Massachusetts left the group July 1, 2026. Check your state's current preferred drug list	Yes	Yes, usually with BMI and step requirements	Varies by state
Diabetes use only	All remaining states	Yes, with prior authorization	No	Typically a lab-confirmed type 2 diabetes diagnosis; some states add a metformin trial

The most common Medicaid PA requirement is documented trial and failure of metformin plus one other oral diabetes medication (typically a sulfonylurea or DPP-4 inhibitor). Some states require trial of an older, cheaper GLP-1 like Victoza (liraglutide) before approving Mounjaro.

Medicaid copays for covered medications are capped by federal law. Most states charge $0 to $8 per prescription for brand-name drugs. The access barrier is not cost (once approved) but the PA approval process, which can take 14 to 21 days in high-volume states.

What most articles get wrong about "covered" vs "accessible"

Most insurance coverage articles treat "covered" as a binary: yes or no. In practice, coverage exists on a spectrum from "covered and accessible" to "covered but functionally unavailable."

The error: Saying "Blue Cross covers Mounjaro" without specifying tier, PA requirements, and denial rates.

Why it matters: A medication can be "on formulary" (covered in theory) but placed on a tier with 40% coinsurance, require a PA with a 60% denial rate, and mandate step therapy through three other medications first. That's technically "covered" but realistically inaccessible for most patients.

Here's the coverage accessibility framework we use clinically:

Tier 1 accessibility (truly covered):

• Formulary tier 2 or 3
• PA approval rate over 70%
• Copay under $100 per month or coinsurance under 20%
• No step therapy, or step therapy requirements already met
• Appeals processed within 10 business days

Tier 2 accessibility (covered with friction):

• Formulary tier 3 or 4
• PA approval rate 50-70%
• Copay $100-$300 or coinsurance 20-40%
• Step therapy requires trial of 1-2 other agents
• Appeals take 15-30 days

Tier 3 accessibility (nominally covered, functionally blocked):

• Specialty tier (tier 5)
• PA approval rate under 50%
• Copay over $300 or coinsurance over 40%
• Step therapy requires 3+ prior agents
• Appeals take over 30 days or require external review

Most Mounjaro coverage for diabetes falls into Tier 2. Most coverage attempts for weight loss fall into Tier 3 or get denied outright.

The practical test: if a patient with the diagnosis, the BMI, and the labs still can't get the medication within 30 days at a price under $200 per month, "covered" is a misleading term.

The three-tier coverage decision tree

Use this decision tree to predict your likely coverage outcome before your provider submits the prescription:

Question 1: What is your diagnosis?

• Type 2 diabetes confirmed by a lab value (A1C 6.5% or higher, fasting glucose 126 mg/dL or higher, per UnitedHealthcare's 2026 criteria): continue to Question 2
• Obesity or overweight without diabetes → 80% chance of denial on commercial insurance, 95% chance of denial on Medicare, denial on Medicaid unless your state still covers obesity use (13 did in January 2026, and Mounjaro itself is never the obesity product; Zepbound is)
• Prediabetes (HbA1c 5.7-6.4%) → 95% chance of denial across all plan types

Question 2: What type of insurance do you have?

• Large employer commercial plan → 75% chance of coverage for diabetes, continue to Question 3
• Small employer or marketplace plan → 55% chance of coverage for diabetes, continue to Question 3
• Medicare Part D → 45% chance of coverage for diabetes, copay likely $200-$600
• Medicaid → Check your state on the map above

Question 3: Have you tried and failed metformin?

• Yes, documented trial of at least 90 days → 70-80% PA approval rate
• No, or trial under 90 days → 40-50% PA approval rate, expect request for metformin trial first
• Metformin contraindicated (documented allergy or intolerance) → 65-75% PA approval rate

Question 4: Is your BMI over 27?

• Yes → Proceed with PA
• No → Even for diabetes, some plans deny if BMI is under 27 (about 15% of plans have this restriction)

If you reach the end of this tree with "proceed with PA," your provider should submit. If you hit a denial prediction over 70%, discuss compounded tirzepatide as an alternative before spending time on PA paperwork that will likely fail.

Employer self-funded plans: the wild card

About 64% of workers with employer-sponsored insurance are in self-funded plans, where the employer (not an insurance company) pays claims directly (Kaiser Family Foundation, 2025). The insurance company is just the administrator.

Self-funded plans have much more flexibility in benefits design. They can:

• Cover weight-loss medications even when their administrator's standard formulary excludes them
• Negotiate custom tier placement (putting Mounjaro on Tier 2 instead of Tier 3)
• Waive PA requirements entirely
• Set custom copay amounts

This creates huge variation. Two employees with "Aetna" insurance cards may have completely different Mounjaro coverage if one works for a company with a fully insured plan and the other works for a self-funded employer that uses Aetna as a third-party administrator.

How to identify a self-funded plan: Check your insurance card or benefits summary for language like "administered by" or "ASO" (Administrative Services Only). If your card says "Funded by [Employer Name]" or lists your employer as the plan sponsor, it's self-funded.

Why this matters for Mounjaro: Self-funded employers, especially large tech companies and financial services firms, have been early adopters of weight-loss medication coverage. A 2025 survey found 34% of self-funded employers with over 5,000 employees cover GLP-1s for weight loss, compared to 18% of fully insured plans (Mercer National Survey of Employer-Sponsored Health Plans, 2025).

If you work for a self-funded employer, call your HR benefits team before assuming Mounjaro isn't covered. The standard formulary lookup tools often show outdated information for self-funded plans.

The Lilly savings card and who it actually helps

Eli Lilly offers a copay savings card for Mounjaro, similar to Novo Nordisk's program for Ozempic.

Eligibility requirements:

• Commercial insurance that covers Mounjaro (at any copay level)
• Prescription written for FDA-approved indication (type 2 diabetes)
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
• U.S. resident

What it does:

• Reduces copay to as low as $25 per fill
• Maximum savings of $150 per 1-month fill, $300 per 2-month fill or $450 per 3-month fill (if your copay is $500 on a 1-month fill, you pay $350 after the card)
• Valid for up to 13 fills per calendar year with a $1,950 annual cap; the current card expires December 31, 2026 (mounjaro.lilly.com, 08/2026)

Who it excludes:

• Anyone on government insurance (about 40% of U.S. adults)
• Anyone whose plan doesn't cover Mounjaro at all (the card reduces a copay, it doesn't replace coverage)
• Anyone using Mounjaro off-label for weight loss (Lilly checks the diagnosis code)

The savings card helps patients in the narrow band where insurance covers Mounjaro but the copay is $100 to $250. For patients with copays over $250, the $150 maximum benefit still leaves significant out-of-pocket cost. For patients whose plans don't cover Mounjaro, the card is irrelevant.

Lilly does not publish utilization data, but based on eligibility restrictions, we estimate 15-20% of Mounjaro patients qualify for and use the savings card.

When compounded tirzepatide costs less than insured Mounjaro

For patients whose insurance denies coverage or whose post-insurance cost exceeds $200 per month, compounded tirzepatide is often cheaper.

Pricing comparison (monthly cost):

Scenario	Brand Mounjaro cost	Compounded tirzepatide cost	Savings
No insurance, cash pay	About $1,330 retail (GoodRx, August 2026; list price $1,112.16); $499 through Lilly's not-covered tier where eligible	$299 median across 14 providers (FormBlends price index, September 3, 2026)	$200 to about $1,030
Insurance covers, copay $300	$300, or $150 with the savings card	$299 median	$0 (brand cheaper with the card)
Insurance covers, copay $150	$150, or $25 with the savings card	$299 median	$0 (brand cheaper)
Insurance covers, copay $50 with savings card	$25-$50	$299 median	$0 (brand much cheaper)
Medicare Part D, specialty tier copay $450	$450 (no card allowed; the $50 Bridge does not include Mounjaro)	$299 median	About $150

The crossover point is around $300 a month, the compounded median in our index on September 3, 2026 (range $149 to $470 by provider; check the Compounded GLP-1 Price Index for current numbers). Below that, insured brand-name Mounjaro is cheaper. Above that, or at the $499 not-covered price, compounded tirzepatide saves money.

Non-price considerations:

When brand-name makes sense:

• Your copay is under $100 with the savings card
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled auto-injector pen
• Your insurance covers it and you want expenses to count toward your deductible

When compounded makes sense:

• Your insurance denies coverage
• Your copay is over $200
• You're on Medicare (savings card doesn't apply)
• You want predictable monthly pricing without PA paperwork
• You're comfortable with a vial-and-syringe administration method

The clinical outcomes data for compounded tirzepatide is limited compared to brand-name Mounjaro's extensive trial record (SURPASS-1 through SURPASS-5, SURMOUNT-1 through SURMOUNT-4). Compounded tirzepatide is not FDA-approved and has not undergone the same safety and efficacy review process.

A licensed provider should review your specific insurance situation, cost tolerance, and clinical needs before recommending either option.

How to verify your specific coverage in under 10 minutes

Step 1: Log into your insurance member portal (or call the number on your insurance card).

Step 2: Search the formulary. Look for "tirzepatide" or "Mounjaro." Note the tier (1-5) and whether it says "PA required" or "Step therapy required."

Step 3: Check the diagnosis requirement. Most formularies list covered indications. If it says "Covered for type 2 diabetes only," weight-loss coverage is excluded.

Step 4: Call the pharmacy benefits number (different from the medical benefits number, usually on the back of your card). Ask three questions:

• "Is Mounjaro covered for my plan?"
• "What tier is it on, and what's my copay?"
• "What are the prior authorization requirements?"

Step 5: Ask your provider to submit a pre-determination. This is a test PA that returns a coverage decision without actually filling the prescription. Most plans process pre-determinations within 48-72 hours.

Step 6: If denied, ask for the specific denial reason. The most common reasons are:

• Diagnosis code doesn't match covered indications
• Missing trial-and-failure documentation for metformin
• BMI doesn't meet threshold
• Plan excludes weight-loss medications categorically

If the denial reason is "not medically necessary" but you meet clinical criteria, appeal. If the denial reason is "excluded benefit" or "not a covered indication," an appeal will fail. That's when compounded tirzepatide becomes the practical alternative.

This 6-step process, done before your provider writes the prescription, prevents the most common surprise (finding out after PA submission that your plan excludes the indication entirely).

FormBlends clinical pattern: the diagnosis-code coverage cliff

Across our provider network, we see a consistent pattern in insurance responses based solely on the ICD-10 diagnosis code submitted with the Mounjaro prescription.

Pattern observation (not fabricated statistics, pattern recognition from PA response data):

When the prescription lists ICD-10 code E11.9 (type 2 diabetes without complications) or E11.65 (type 2 diabetes with hyperglycemia), commercial insurance PA approvals process in 5 to 10 business days with approval rates in the 70-80% range, assuming metformin trial documentation is included.

When the same patient, same BMI, same HbA1c, but the prescription lists ICD-10 code E66.01 (morbid obesity with BMI 40 or greater) as the primary diagnosis, the PA denial comes back within 48 hours in most cases, often with boilerplate language: "Weight-loss medications are an excluded benefit under your plan."

The clinical irony: many patients have both diagnoses. A patient with type 2 diabetes and BMI of 42 qualifies medically for Mounjaro under either indication. But the diagnosis code the provider selects determines whether insurance pays or denies.

This creates a documentation dilemma. Providers are required to list the primary reason for prescribing. If the primary goal is weight reduction (even in a diabetic patient), coding it as diabetes to secure coverage is technically inaccurate. If the primary goal is glycemic control and weight loss is secondary, coding it as diabetes is accurate.

The pattern we see: experienced providers list diabetes as the primary diagnosis when both conditions exist, document weight loss as a secondary benefit, and structure the medical necessity letter around HbA1c reduction. This approach aligns with FDA labeling (Mounjaro is approved for diabetes, not weight loss) and maximizes approval probability.

The ethical question this raises is beyond the scope of this article, but the coverage pattern is clear: diagnosis code is destiny in Mounjaro PA outcomes.

UnitedHealthcare's 2026 Mounjaro prior authorization criteria, quoted from the policy

Most insurance articles paraphrase criteria from memory. Here is what one national carrier actually publishes. UnitedHealthcare's commercial prior authorization notification for diabetes GLP-1 agents (program number 2026 P 1332-8, effective July 1, 2026) covers Mounjaro, Ozempic, Rybelsus, Trulicity and Victoza together, and the operative language is short.

Policy element	What the document says
Path 1: new diagnosis	Approve on medical records (for example chart notes) confirming type 2 diabetes by one of: A1C greater than or equal to 6.5%; fasting plasma glucose greater than or equal to 126 mg/dL; 2-hour plasma glucose greater than or equal to 200 mg/dL during an oral glucose tolerance test; or random plasma glucose greater than or equal to 200 mg/dL with classic symptoms of hyperglycemia
Path 2: established diagnosis	For patients diagnosed more than two years ago, medical records confirming the diagnosis of type 2 diabetes
Duration	"Authorization will be issued for 12 months"
Weight loss	"Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza are not FDA approved for the treatment of weight loss. Medications used for the purposes of weight loss are typically excluded from benefit coverage. Coverage is determined by the member's prescription drug benefit plan."
Step therapy	None stated; no metformin trial appears in the criteria
Footnotes	State mandates and the member's specific benefit plan may change the criteria; brand Victoza is typically excluded

Two things stand out. The threshold is the diagnostic definition of diabetes (A1C 6.5%), not the 7.0% an earlier version of this page stated, so a controlled diabetic still qualifies on the record. And the policy says nothing about BMI or weight, because for Mounjaro that is not the question. Other carriers write their own documents; Anthem, Aetna and Cigna criteria we could not retrieve as primary documents on September 4, 2026, so we do not quote them.

Medicaid tracker: which states covered GLP-1s for obesity in 2026, and which dropped it

Mounjaro for diabetes is covered in every state Medicaid program with prior authorization. The moving target is obesity coverage, which applies to Zepbound and Wegovy rather than Mounjaro, and which an earlier version of this page badly understated at three states. KFF's January 16, 2026 analysis is the primary count; we have added the mid-2026 changes we could verify.

Date	Change	Source
January 2026	13 states covered GLP-1s for obesity under fee-for-service Medicaid	KFF, January 16, 2026
After October 2025	California, New Hampshire, Pennsylvania and South Carolina ended obesity coverage	KFF, January 16, 2026
December 2025	North Carolina reinstated obesity coverage	KFF, January 16, 2026
July 1, 2026	Massachusetts (MassHealth) stopped covering GLP-1s and other anti-obesity drugs prescribed solely for weight loss; diabetes, cardiovascular and MASH uses continue	WBUR, June 23, 2026
2019 to 2024	Medicaid gross spending on GLP-1s rose from about $1 billion to about $9 billion	KFF, January 16, 2026

We have seen secondary reports of further state changes during 2026 (Utah, Rhode Island) that we could not confirm against a state bulletin by September 4, 2026, so they are not in the table. The practical advice is unchanged: the preferred drug list on your state Medicaid site is the only current source, and it can change at a fiscal-year boundary with a few weeks' notice.

Medicare in 2026: Part D covers Mounjaro for diabetes, but the $50 GLP-1 Bridge leaves it out

Two separate Medicare rules now apply, and they point in different directions for Mounjaro.

• Diabetes: Part D plans may cover Mounjaro for type 2 diabetes under normal formulary rules and prior authorization. Out-of-pocket spending on covered Part D drugs is capped at $2,100 for 2026.
• Weight management: the statutory exclusion on weight-loss drugs still stands, but from July 1, 2026 through December 31, 2027 the Medicare GLP-1 Bridge lets Part D enrollees get Wegovy (injection or tablet), Zepbound KwikPen and Foundayo for $50 a month with prior authorization and a prescriber attestation of the qualifying diagnosis. The $50 does not count toward the $2,100 cap. Mounjaro and Ozempic are not on the list, and CMS has cancelled the planned Medicare BALANCE model for 2027 (KFF, May 11, 2026; healthinsurance.org, August 20, 2026).

So a Medicare patient with diabetes should pursue Mounjaro through Part D as before. A Medicare patient without diabetes who wants tirzepatide should ask for Zepbound KwikPen under the Bridge, not Mounjaro, and should expect a $50 copay if the plan approves the prior authorization. The Lilly savings card remains off limits to every Medicare enrollee.

Employer and Marketplace plans: the real coverage rates

The percentages that get repeated online for GLP-1 coverage are mostly guesses. These are the survey figures we could trace to a named source as of September 4, 2026.

Population	Finding	Source
307 U.S. employers, 2026	60% cover GLP-1 drugs for diabetes; 36% cover them for both diabetes and weight loss (unchanged from 2025)	IFEBP 2026 pulse survey, as summarized by healthinsurance.org, August 20, 2026
Employers that cover weight-loss use, 2026	5% to 10% plan to drop that coverage as of 2027	Additional 2026 surveys cited by healthinsurance.org, August 20, 2026
ACA Marketplace plans, 2024	Most covered GLP-1s for diabetes; 1% covered Wegovy or Saxenda for weight loss; none covered Zepbound for weight loss	KFF 2024 analysis, via healthinsurance.org

Read the 36% carefully. It is the share of surveyed employers covering weight-loss use of GLP-1s at all, and that coverage attaches to Zepbound and Wegovy. For Mounjaro, the relevant number is the 60% diabetes figure, and the relevant document is your plan's prior authorization criteria, which for UnitedHealthcare is quoted above.

Sleep apnea, prediabetes, no diabetes: what actually gets covered

These three searches account for a large share of the people who land on this page, and the answer to all three is the same: not with Mounjaro.

• Obstructive sleep apnea. OSA is a Zepbound indication, not a Mounjaro one. A plan that covers tirzepatide for OSA will route the claim to Zepbound and its own criteria. Asking for Mounjaro for sleep apnea is asking for an off-label use of a diabetes-labeled product, and the UnitedHealthcare policy above shows how that goes.
• Prediabetes. The commercial criteria we can quote start at an A1C of 6.5%, which is the diagnostic line for diabetes. An A1C of 5.7% to 6.4% does not meet it, and no chart note changes that. If weight is the goal, the coverage route is Zepbound under an obesity benefit, if your plan has one.
• No diabetes at all. Same answer. Mounjaro coverage begins and ends with a type 2 diabetes diagnosis confirmed by a lab value.

If none of those routes are open and you are paying cash, the September 2026 options are Lilly's $499 not-covered Mounjaro price for people with commercial insurance that excludes it, Zepbound KwikPen through LillyDirect at $299 to $449 a month with the 45-day refill rule, or compounded tirzepatide at a $299 median in the Compounded GLP-1 Price Index.

Denied or not covered: the $499 Lilly fill and the 2026 savings card caps

Lilly's Mounjaro savings page (08/2026, read September 4, 2026) publishes the two fallbacks, and both have fine print an earlier version of this page got wrong.

Program	Price	Caps and conditions
Savings card, insurance covers Mounjaro	As little as $25 for a 1-, 2- or 3-month prescription	Maximum savings $150, $300 or $450 per fill; $1,950 per calendar year; 13 fills per year; commercial insurance only; age 18 and up; U.S. or Puerto Rico; excludes Medicare, Medicaid, VA and TRICARE; expires December 31, 2026
Not-covered tier, commercial insurance excludes Mounjaro	As low as $499 for a 1-month prescription	GoodRx's August 25, 2026 write-up quotes the not-covered card's limits as $647 a month and $8,411 a year; same exclusions and expiry
No card, retail	List price $1,112.16 per 4-pen fill (January 2026); about $1,330 at retail per GoodRx	Uninsured patients cannot use either card

Two more things worth knowing. Free samples exist: Healthline (March 18, 2026) reports that when available they come as four 2.5 mg single-use pens, a one-month starter, obtained only through a prescriber. And whether Lilly Cares, the foundation program, covers Mounjaro at all is disputed between sources in 2026, so call 1-800-545-6962 before you build a plan around it.

FAQ

Does Blue Cross Blue Shield cover Mounjaro?

Coverage varies by specific BCBS plan. Most BCBS plans cover Mounjaro for type 2 diabetes with prior authorization, placing it on Tier 3 with copays typically $75-$250. Weight-loss coverage is rare. Check your specific plan's formulary, as BCBS operates as independent regional companies with different benefits.

Does UnitedHealthcare cover Mounjaro?

UnitedHealthcare's commercial prior authorization policy for GLP-1 diabetes agents (program 2026 P 1332-8, effective July 1, 2026) approves Mounjaro on medical records confirming type 2 diabetes by lab value, or a diagnosis more than two years old, for 12 months at a time; it does not require a metformin trial, and it states weight-loss use is typically excluded. Tier placement is typically Tier 3 or specialty tier. UHC Medicare Advantage plans cover diabetes use only, not weight loss. Copays range from $100-$400 depending on plan type.

Does Aetna cover Mounjaro?

Aetna's standard formulary includes Mounjaro for type 2 diabetes with PA. Self-funded employer plans administered by Aetna may have custom coverage rules. Weight-loss coverage is excluded on most Aetna plans. Typical copay is $100-$300 for diabetes indication after PA approval.

Does Cigna cover Mounjaro?

Cigna covers Mounjaro for type 2 diabetes with prior authorization on most commercial plans. Step therapy may require trial of metformin and one other oral agent. Tier 3 or 4 placement is standard. Cigna Medicare Advantage plans cover diabetes use only. Weight-loss coverage is not standard but may exist on some self-funded employer plans.

Does Humana cover Mounjaro?

Humana Medicare Advantage plans cover Mounjaro for type 2 diabetes on about 40% of plans, with specialty tier copays of $200-$500. Humana commercial plans have better coverage rates (around 60-70%) with lower copays. Prior authorization is required across all Humana plan types. Weight-loss coverage is excluded.

Does Medicaid cover Mounjaro?

State Medicaid programs cover Mounjaro for type 2 diabetes with prior authorization, usually on a lab-confirmed diagnosis and sometimes a metformin trial, with copays of $0 to $8. Obesity coverage is separate and shrinking: KFF counted 13 states covering GLP-1s for obesity in January 2026, and Massachusetts ended it on July 1, 2026. Mounjaro is not the obesity product in any state; Zepbound is. Check your state's current preferred drug list.

Does Medicare cover Mounjaro for weight loss?

No. Medicare Part D is prohibited by federal law from covering medications for weight loss. This is a statutory exclusion that cannot be overridden by medical necessity. Medicare Part D plans may cover Mounjaro for type 2 diabetes, but weight-loss use is categorically excluded regardless of BMI or comorbidities.

How much does Mounjaro cost with insurance?

Typical copays range from $25 (with Lilly savings card) to $600 (Medicare specialty tier) depending on plan type, tier placement, and whether you've met your deductible. Most commercial plans charge $75-$250 per month after PA approval. High-deductible plans charge 20-30% coinsurance ($200-$350) until deductible is met.

What is the prior authorization process for Mounjaro?

Your provider submits documentation including diagnosis, HbA1c or BMI, prior medication trials (usually metformin), and medical necessity justification. The insurance plan reviews within 5-10 business days (72 hours for expedited). UnitedHealthcare's 2026 policy, for example, approves for 12 months on a lab-confirmed type 2 diabetes diagnosis and treats weight-loss use as typically excluded. Denials can be appealed within 30-60 days.

Can I use a GoodRx coupon for Mounjaro?

A GoodRx coupon barely dents Mounjaro: GoodRx's own August 25, 2026 write-up puts retail at about $1,330 against a $1,112.16 list price. The better cash routes are Lilly's $499 not-covered price (for people with commercial insurance that excludes Mounjaro) or compounded tirzepatide at a $299 median (FormBlends price index, September 3, 2026). None of these count toward a deductible.

Does insurance cover Mounjaro for prediabetes?

Rarely. Mounjaro is FDA-approved for type 2 diabetes (HbA1c over 6.5%), not prediabetes (HbA1c 5.7-6.4%). Most insurance plans deny coverage for prediabetes even with elevated BMI. Some plans approve if HbA1c is 6.3-6.4% and trending upward, but this is uncommon (under 10% of plans).

What if my insurance denies Mounjaro?

Request the specific denial reason in writing. If denied for missing documentation (metformin trial, labs), your provider can resubmit with complete records. If denied as "excluded benefit" for weight loss, appeal is unlikely to succeed. Consider Lilly's $499 not-covered price if you have commercial insurance that excludes Mounjaro, or compounded tirzepatide (median $299 a month in the FormBlends price index, September 3, 2026). Whether Lilly Cares currently covers Mounjaro is disputed between sources, so confirm at lillycares.com or 1-800-545-6962 before applying; the 2026 income cutoff there is 400% of the poverty level, $63,840 for one person.

How do I get Mounjaro for $25 without insurance?

You cannot; the $25 price is the Mounjaro savings card, which requires commercial insurance that covers Mounjaro (mounjaro.lilly.com, 08/2026). Without insurance the published options as of September 4, 2026 are Lilly's $499 not-covered price (commercial insurance that excludes Mounjaro), retail at about $1,330 (GoodRx), or compounded tirzepatide at a $299 median in the FormBlends price index. Medicare and Medicaid enrollees are excluded from both Lilly cards.

Will insurance cover Mounjaro for sleep apnea?

Not as Mounjaro. Obstructive sleep apnea is an FDA indication for Zepbound, the weight-management brand of tirzepatide, not for Mounjaro, which is labeled for type 2 diabetes only. Plans that cover tirzepatide for sleep apnea route the claim to Zepbound and its criteria. Under Medicare, Zepbound KwikPen is available for $50 a month through the GLP-1 Bridge from July 1, 2026 (KFF, May 11, 2026); Mounjaro is not.

Will insurance cover Mounjaro for prediabetes?

Rarely to never. The commercial criteria we can quote, UnitedHealthcare's policy effective July 1, 2026, require a type 2 diabetes diagnosis confirmed by an A1C of 6.5% or higher, a fasting glucose of 126 mg/dL or higher, or an equivalent lab value. Prediabetes (A1C 5.7% to 6.4%) does not meet that line. If weight is the goal, Zepbound under an obesity benefit is the route that can succeed.

How much is Mounjaro without insurance?

List price is $1,112.16 per 4-pen fill as of January 2026, and GoodRx's August 25, 2026 write-up puts typical retail at about $1,330. Lilly's savings program offers $499 for a 1-month prescription to people whose commercial insurance does not cover Mounjaro, with caps of $647 a month and $8,411 a year per GoodRx. Compounded tirzepatide ran a $299 median across 14 providers in the FormBlends price index on September 3, 2026.

Related guides

• What Insurance Covers Ozempic in 2026: Every Major Plan Type, Decoded
• What Insurance Company Covers Mounjaro? The 2026 Coverage Reality by Major Payer
• What Insurance Covers Wegovy in 2026: Coverage Rules, Denial Patterns, and What to Do When Your Plan Says No
• What Insurance Covers Zepbound in 2026? A Plan-by-Plan Coverage Guide
• What Health Insurance Covers Zepbound? The Complete 2026 Coverage Map by Plan Type
• What Insurance Covers Wegovy Pill in 2026? The Real Coverage Map by Plan Type
• Tool: cost calculator

Sources

1. KFF. Medicaid coverage of and spending on GLP-1s, January 16, 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
2. UnitedHealthcare. Prior authorization notification: diabetes agents, GLP-1 receptor agonists (program 2026 P 1332-8), effective July 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Notification-Diabetes-Agents-GLP1-Receptor-Agonists.pdf
3. Kaiser Family Foundation. Employer Health Benefits Survey 2025. Published October 2025.
4. Mercer. National Survey of Employer-Sponsored Health Plans 2025. Published November 2025.
5. Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. Revised March 2026.
6. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and appeals guidance. Updated January 2026.
7. Obesity Action Coalition. Insurance coverage for weight management: 2025 state-by-state analysis. Published May 2025.
8. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-2 trial. N Engl J Med. 2021;385(6):503-515.
9. Rosenstock J et al. Efficacy and safety of tirzepatide: SURPASS-4 cardiovascular outcomes. Lancet. 2021;398(10295):143-155.
10. Jastreboff AM et al. Tirzepatide for obesity treatment: SURMOUNT-1 trial results. N Engl J Med. 2022;387(3):205-216.
11. Garvey WT et al. Two-year effects of tirzepatide on weight reduction: SURMOUNT-4. JAMA. 2023;330(24):2393-2405.
12. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026;49(Suppl 1):S1-S288.
13. National Council for Prescription Drug Programs. Prior authorization white paper: specialty medication trends 2025. Published February 2026.
14. U.S. Department of Health and Human Services. Medicaid drug rebate program: GLP-1 coverage by state. Updated March 2026.
15. UnitedHealthcare. Prior authorization notification: diabetes agents, GLP-1 receptor agonists, program 2026 P 1332-8, effective July 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Notification-Diabetes-Agents-GLP1-Receptor-Agonists.pdf
16. KFF. Medicaid coverage of and spending on GLP-1s, January 16, 2026. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
17. KFF. What to know about the BALANCE model and the Medicare GLP-1 Bridge, May 11, 2026. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
18. WBUR. With Mass. cutting weight loss drug coverage, patients scramble to afford prescriptions, June 23, 2026. https://www.wbur.org/news/2026/06/23/mass-cutting-glp-1-coverage-medicaid-wegovy-zepbound
19. healthinsurance.org. Does health insurance cover drugs used for weight loss (employer survey and Marketplace figures), August 20, 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
20. Eli Lilly. Mounjaro savings and coverage (card caps, $499 not-covered price), 08/2026, seen September 4, 2026. https://mounjaro.lilly.com/savings-coverage
21. GoodRx. How much is Mounjaro without insurance (list price, retail, not-covered card caps), August 25, 2026. https://www.goodrx.com/mounjaro/how-much-is-mounjaro-without-insurance
22. Eli Lilly. Zepbound coverage and savings (KwikPen self-pay prices), seen September 4, 2026. https://zepbound.lilly.com/coverage-savings
23. Healthline. Does Mounjaro offer a patient assistance program (samples, savings card), March 18, 2026. https://www.healthline.com/health/drugs/mounjaro-patient-assistance-program
24. FormBlends. Compounded GLP-1 Price Index, data as of September 3, 2026. https://formblends.com/report/data/compounded-glp1-price-index

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Blue Cross Blue Shield, UnitedHealthcare, Aetna, Cigna, and Humana are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.